17 research outputs found
A NOVEL INDEX OF ABUNDANCE OF JUVENILE YELLOWFIN TUNA IN THE ATLANTIC OCEAN DERIVED FROM ECHOSOUNDER BUOYS
The collaboration with the Spanish vessel-owners associations and the buoy-providers
companies, has made it possible the recovery of the information recorded by the satellite linked
GPS tracking echosounder buoys used by the Spanish tropical tuna purse seiners and associated
fleet in the Atlantic since 2010. These instrumental buoys inform fishers remotely in real-time
about the accurate geolocation of the FAD and the presence and abundance of fish aggregations
underneath them. Apart from its unquestionable impact in the conception of a reliable CPUE
index from the tropical purse seine tuna fisheries fishing on FADs, echosounder buoys have also
the potential of being a privileged observation platform to evaluate abundances of tunas and
accompanying species using catch-independent data. Current echosounder buoys provide a
single acoustic value without discriminating species or size composition of the fish underneath
the FAD. Therefore, it has been necessary to combine the echosounder buoys data with fishery
data, species composition and average size, to obtain a specific indicator. This paper presents a
novel index of abundance of juvenile yellowfin tuna in the Atlantic Ocean derived from
echosounder buoys for the period 2010-2018
The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry
Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0 % were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5 %). The diagnosis was deep-vein thrombosis (DVT) in 59.5 % and pulmonary embolism (PE) in 40.5 %. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5 %), hypertension (42.3 %) and dyslipidaemia (21.1 %). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2 %), almost half received a vitamin K antagonist (48.7 %) and nearly a quarter received a DOAC (24.5 %). Almost a quarter of all presentations were for recurrent VTE, with >80 % of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes
The curcumin analog DM-1 induces apoptotic cell death in melanoma
The main difficulty in the successful treatment of metastatic melanoma is that this type of cancer is known to be resistant to chemotherapy. Chemotherapy remains the treatment of choice, and dacarbazine (DTIC) is the best standard treatment. The DM-1 compound is a curcumin analog that possesses several curcumin characteristics, such as antiproliferative, antitumor, and antimetastatic properties. The objective of this study was to evaluate the signaling pathways involved in melanoma cell death after treatment with DM-1 compared to the standard agent for melanoma treatment, DTIC. Cell death was evaluated by flow cytometry for annexin V and iodide propide, cleaved caspase 8, and TNF-R1 expression. Hoechst 33342 staining was evaluated by fluorescent microscopy; lipid peroxidation and cell viability (MTT) were evaluated by colorimetric assays. The antiproliferative effects of the drugs were evaluated by flow cytometry for cyclin D1 and Ki67 expression. Mice bearing B16F10 melanoma were treated with DTIC, DM-1, or both therapies. DM-1 induced significant apoptosis as indicated by the presence of cleaved caspase 8 and an increase in TNF-R1 expression in melanoma cells. Furthermore, DM-1 had antiproliferative effects in this the same cell line. DTIC caused cell death primarily by necrosis, and a smaller melanoma cell population underwent apoptosis. DTIC induced oxidative stress and several physiological changes in normal melanocytes, whereas DM-1 did not significantly affect the normal cells. DM-1 antitumor therapy in vivo showed tumor burden decrease with DM-1 monotherapy or in combination with DTIC, besides survival rate increase. Altogether, these data confirm DM-1 as a chemotherapeutic agent with effective tumor control properties and a lower incidence of side effects in normal cells compared to DTIC
A new animal model of atrophy–hypertrophy complex and liver damage followingYttrium‐90 lobar selective internal radiation therapy in rabbits
Lobar selective internal radiation therapy (SIRT) is widely used to treat liver tumors inducing atrophy
of the treated lobe and contralateral hypertrophy. The lack of animal model has precluded further
investigations to improve this treatment. We developed an animal model of liver damage and
atrophy–hypertrophy complex after SIRT. Three groups of 5–8 rabbits received transportal SIRT with
Yttrium 90 resin microspheres of the cranial lobes with diferent activities (0.3, 0.6 and 1.2GBq),
corresponding to predicted absorbed radiation dose of 200, 400 and 800 Gy, respectively. Another
group received non-loaded microspheres (sham group). Cranial and caudal lobes volumes were
assessed using CT volumetry before, 15 and 30 days after SIRT. Liver biochemistry, histopathology
and gene expression were evaluated. Four untreated rabbits were used as controls for gene expression
studies. All animals receiving 1.2GBq were euthanized due to clinical deterioration. Cranial SIRT with
0.6GBq induced caudal lobe hypertrophy after 15 days (median increase 34% -ns-) but produced
signifcant toxicity. Cranial SIRT with 0.3GBq induced caudal lobe hypertrophy after 30 days
(median increase 82%, p = 0.04). No volumetric changes were detected in sham group. Transient
increase in serum transaminases was detected in all treated groups returning to normal values at
15 days. There was dose-dependent liver dysfunction with bilirubin elevation and albumin decrease.
Histologically, 1.2GBq group developed permanent severe liver damage with massive necrosis, 0.6
and 0.3GBq groups developed moderate damage with infammation and portal fbrosis at 15 days,
partially recovering at 30 days. There was no diference in the expression of hepatocyte function and
diferentiation genes between 0.3GBq and control groups. Cranial SIRT with 0.3GBq of 90Y resin
microspheres in rabbits is a reliable animal model to analyse the atrophy–hypertrophy complex and
liver damage without toxicity
A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study
Although there is published research on the impact of venous thromboembolism (VTE) on quality of life (QoL), this issue has not been thoroughly investigated in patients with cancer-particularly using specific questionnaires. We aimed to examine the impact of acute symptomatic VTE on QoL of patients with malignancies. This was a multicenter, prospective, case-control study conducted in patients with cancer either with (cases) or without (controls) acute symptomatic VTE. Participants completed the EORTC QLQ-C30, EQ-5D-3L, PEmb-QoL, and VEINES-QOL/Sym questionnaires. Statistically significant and clinically relevant differences in terms of global health status were examined. Between 2015 and 2018, we enrolled 425 patients (128 cases and 297 controls; mean age: 60.2 +/- 18.4 years). The most common malignancies were gastrointestinal (23.5%) and lung (19.8%) tumors. We found minimally important differences in global health status on the EQ-5D-3L (cases versus controls: 0.55 versus 0.77; mean difference: -0.22) and EORTC QLQ-C30 (47.7 versus 58.4; mean difference: -10.3) questionnaires. There were minimally important differences on the PEmb-QoL questionnaire (44.4 versus 23; mean difference: -21.4) and a significantly worse QoL on the VEINES-QOL/Sym questionnaire (42.7 versus 51.7; mean difference: -9). In conclusion, we showed that acute symptomatic VTE adversely affects the QoL of patients with malignancies